In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.

In the SCENARIO trial, a 15-week weight-loss program cut recurrent vascular events by 67% in patients with obesity after minor ischemic stroke or TIA.

Edaravone dexborneol before thrombectomy improved 90-day independence only in LVO stroke patients with clinical-radiological mismatch in TASTE-2.

Skin clearance and route of administration drove treatment choices among 202 patients with psoriasis in the ENCOMPASS-PP discrete choice experiment.

Alexa Kimball, MD, MPH, reviews tulisokibart safety in hidradenitis suppurativa, its potential in patients with IBD, and what phase 3 trials must answer.

In this segment of her interview, Kimball discusses phase 2b tulisokibart data in hidradenitis suppurativa and the rationale for targeting TL1A.

Oral prifemilast, a PDE4B-selective inhibitor, led to PASI 75 attainment in up to 57.4% of those with psoriasis at week 16 vs 10.8% with placebo.

Michael Wechsler, MD, discusses SWIFT/AGILE data showing 59% of patients in remission with depemokimab at year 1 maintained it at year 2.